Higher-riskArticle link

Brexpiprazole for Agitation in Alzheimer's Dementia: What Family Caregivers Need to Know

If your loved one with Alzheimer's dementia is experiencing agitation—restlessness, pacing, shouting, or even hitting—you may be wondering if brexpiprazole (Rexulti) can help. This article explains what the research shows about this medication, how it compares to other options, and the concrete steps you can take to address agitation safely. You are not alone, and there are practical things you can try, from non-drug strategies to informed conversations with your doctor.

Key points

  • Brexpiprazole (Rexulti) is FDA-approved for agitation in Alzheimer's dementia, but it is not a first-line treatment—always try non-drug strategies and rule out medical causes first.
  • Clinical trials show brexpiprazole can reduce agitation and caregiver distress over 12 weeks, but it carries a boxed warning for increased mortality risk in older adults with dementia.
  • Start at the lowest effective dose, monitor closely for side effects (sedation, dizziness, confusion, falls), and combine with ongoing non-drug approaches.
  • Never stop brexpiprazole suddenly; taper off under medical supervision to avoid withdrawal symptoms.
  • Keep a detailed log of agitation triggers, responses, and side effects to share with the doctor at every visit.
  • Seek support for yourself as a caregiver—agitation is exhausting, and you deserve help and understanding.

What Is Agitation in Alzheimer's Dementia?

Agitation is a common neuropsychiatric symptom in Alzheimer's dementia, affecting up to 80% of people at some point. It can show up as non-aggressive behaviors like wandering, restlessness, or pacing, or as aggressive behaviors like cursing, shouting, or hitting. These behaviors often cause significant distress for both the person with dementia and their caregivers. Agitation is not a single thing—it can be triggered by pain, infection, delirium, unmet needs (like hunger or thirst), environmental overstimulation, or changes in routine. Before considering medication, it's crucial to rule out these underlying causes, because treating the wrong thing can make things worse.

What Is Brexpiprazole and How Does It Work?

Brexpiprazole (brand name Rexulti) is an atypical antipsychotic medication. It works by modulating dopamine and serotonin receptors in the brain, which can help reduce agitation and aggression. In 2023, the U.S. Food and Drug Administration (FDA) approved brexpiprazole specifically for the treatment of agitation associated with dementia due to Alzheimer's disease. This is a significant development because it is one of only two medications with a primary FDA approval for this indication. The approval was based on two 12-week clinical trials (NCT01862640 and NCT03548584) that showed brexpiprazole led to greater improvements in agitation and aggression compared to placebo, and also reduced caregiver distress. However, like all antipsychotics, brexpiprazole carries a boxed warning about an increased risk of death in older adults with dementia-related psychosis, so it must be used with caution and only after non-drug approaches have been tried.

How Does Brexpiprazole Compare to Other Medications?

Before brexpiprazole, the main medications used off-label for agitation included other antipsychotics like risperidone, olanzapine, quetiapine, and aripiprazole, as well as antidepressants like citalopram and trazodone. Research shows that risperidone and olanzapine have some evidence for reducing agitation, but they also carry significant side effects like sedation, increased confusion, falls, and movement disorders. Citalopram has shown modest benefit but at doses (30 mg/day) that exceed the FDA's recommended maximum for older adults due to heart rhythm risks. Brexpiprazole offers a newer option with a different side effect profile, but it is not a cure-all. It may work better for some individuals than others, and it still requires careful monitoring. The key is that no medication should be the first line of defense—non-drug strategies and addressing underlying causes always come first.

General caregiving information, not medical advice. Check medications and major care changes with your clinician.

Step-by-step

  1. Rule out physical causes first: schedule a doctor visit to check for pain, urinary tract infection, constipation, dehydration, or medication side effects, since people with dementia often signal these through agitation.

  2. Distinguish delirium from baseline agitation: if confusion and attention fluctuate and came on suddenly over hours or days, it is a medical emergency—call the doctor rather than adding an antipsychotic.

  3. Implement non-drug strategies as the foundation: reduce noise and clutter, maintain a consistent routine, offer calming activities (folding laundry, familiar music, short walk, photo album), redirect gently, and ensure basic needs (hunger, thirst, bathroom) are met.

  4. If non-drug steps are insufficient, discuss brexpiprazole with the doctor: ask whether it matches your loved one's symptoms and history, insist on the lowest effective dose (0.5–1 mg once daily), and allow only medically supervised adjustments.

  5. During the first weeks on brexpiprazole, monitor daily for increased confusion, sedation, dizziness, falls, muscle stiffness, or new behavioral changes, and track cognition and function since antipsychotics may accelerate decline.

  6. Reassess need every 1–3 months with the doctor; if agitation improves significantly, request a gradual dose reduction or trial off the medication—never stop suddenly, as withdrawal can cause anxiety, rebound agitation, and physical symptoms.

  7. Prioritize your own stamina: caregiving for agitation is exhausting, so join a support community (e.g., ALZConnected), use respite care, and seek counseling to sustain your ability to care for your loved one.

What not to do

  • Do not use brexpiprazole as a sleep aid or chemical restraint; this is not evidence-based and risks over-sedation, falls, and faster cognitive decline.

  • Do not combine brexpiprazole with other sedating drugs (benzodiazepines, sleep aids, strong pain medications) without explicit doctor approval, due to elevated risks of falls, confusion, and respiratory depression.

  • Do not stop brexpiprazole suddenly; abrupt withdrawal can trigger anxiety, rebound agitation, and physical symptoms—any taper must be planned and supervised by the prescriber.

  • Do not assume brexpiprazole will work for your loved one; clinical trials show it helps some but not all—if no meaningful improvement occurs after 4–6 weeks at a therapeutic dose, discuss switching or stopping with the doctor.

  • Do not disregard the FDA boxed warning that antipsychotics increase mortality risk in older adults with dementia-related psychosis; weigh this against potential benefits, especially in advanced dementia or with multiple comorbidities.

Practical tools

  • Agitation Trigger Log

    For 1–2 weeks before the doctor visit, log the date, time, preceding events (e.g., bath time, routine change, loud TV), what you tried (redirection, snack, walk, calming activity), and the person's response. Patterns guide non-drug strategies and medication decisions.

  • Doctor Discussion Script

    Open with: 'My loved one has agitation not improving with calming activities and routine changes, and we have ruled out pain and infection. Can we discuss whether brexpiprazole is appropriate? I understand the FDA warning and want to start at the lowest dose with close monitoring.'

  • Calming Activity Checklist

    Try these one at a time before medication: offer a warm drink, play familiar music from their younger years, take a short walk, look through a photo album, fold towels together, or give a gentle hand massage. Keep tone calm and reassuring; choose success-oriented activities, not tests.

  • Side-Effect Monitoring Checklist

    For the first weeks on brexpiprazole, check daily for: unusual sleepiness, dizziness/unsteadiness, fall or near-fall, new muscle stiffness/tremor, increased confusion, new restlessness, or appetite/weight change. Bring this checklist to every follow-up visit to guide dose adjustment or discontinuation.

Discuss with your clinician

Ask the doctor: 'What is the specific evidence for brexpiprazole in my loved one's stage of Alzheimer's? Are there any clinical trials that included people like them?'

Discuss the FDA boxed warning about increased mortality risk. Ask: 'How do we weigh this risk against the severity of the agitation?'

Inquire about the starting dose and titration schedule. Ask: 'What is the target dose, and how quickly will we increase it?'

Ask about monitoring: 'What side effects should I watch for, and how often should we have follow-up appointments?'

Discuss potential drug interactions: 'Could brexpiprazole interact with my loved one's current medications, including donepezil, memantine, or any blood thinners?'

If the person has a history of falls, ask: 'How can we minimize fall risk while on this medication?'

Ask about a plan for discontinuation: 'If the agitation improves, how and when would we consider stopping the medication?'

Related guides

Sources